Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,055 recalls · Class II, newest first

Class II · Moderate risk

Fagron

Microbial Contamination of Non-Sterile Products: Fagron is recalling six lots due to the presence of mold.

Terminated Microbial contamination Fagron, Inc NDC 51552-1205-6 D-1496-2014
Class II · Moderate risk

Tetrahydrozoline Hydrochloride

CGMP Deviations; Stored/dispensed in a non-GMP compliant warehouse at S.I.M.S., Italy.

Terminated cGMP deviation Spectrum Laboratory Products D-0255-2015
Class II · Moderate risk

All sterile products within expiry

Lack of Sterility Assurance: A recent FDA inspection revealed poor aseptic production practices that result in lack of sterility assurance of products intended to be sterile.

Terminated Sterility / contamination Unique Pharmaceutical, Ltd D-0012-2015
Class II · Moderate risk

Tetrahydrozoline HCL

CGMP Deviations; Stored/dispensed in a non-GMP compliant warehouse at S.I.M.S., Italy.

Terminated cGMP deviation SST Corporation D-1517-2014
Class II · Moderate risk

Daytrana (methylphenidate transdermal system)

Defective Delivery System: Out of Specification (OOS) results for the mechanical peel force (MPF) and z-statistic value which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration.

Terminated Packaging defect Noven Pharmaceuticals, Inc. NDC 68968-5554-3 D-1608-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-107-30 D-1508-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-106-30 D-1507-2014
Class II · Moderate risk

Benicar Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-104-30 D-1506-2014
Class II · Moderate risk

Welchol Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-701-18 D-1505-2014
Class II · Moderate risk

Tribenzor Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-116-30 D-1504-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-105-30 D-1503-2014
Class II · Moderate risk

Benicar Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-103-30 D-1502-2014
Class II · Moderate risk

Azor Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-113-30 D-1501-2014
Class II · Moderate risk

Clonidine HCL

cGMP Deviations: GYMA laboratories Inc. has recalled multiple Active Pharmaceutical Ingredients manufactured in Italy upon receipt of a Rapid Alert Notification issued by The Italian Medicines Agency due to lack of good manufacturing practices.

Terminated cGMP deviation Gyma Laboratories Of Amer,Inc D-0024-2015
Class II · Moderate risk

Clonidine Base Micronized

cGMP Deviations: GYMA laboratories Inc. has recalled multiple Active Pharmaceutical Ingredients manufactured in Italy upon receipt of a Rapid Alert Notification issued by The Italian Medicines Agency due to lack of good manufacturing practices.

Terminated cGMP deviation Gyma Laboratories Of Amer,Inc NDC 12660-0503-01 D-0023-2015
Class II · Moderate risk

Propranolol HCl

cGMP Deviations: GYMA laboratories Inc. has recalled multiple Active Pharmaceutical Ingredients manufactured in Italy upon receipt of a Rapid Alert Notification issued by The Italian Medicines Agency due to lack of good manufacturing practices.

Terminated cGMP deviation Gyma Laboratories Of Amer,Inc D-0022-2015
Class II · Moderate risk

Dipyridamole API

cGMP Deviations: GYMA laboratories Inc. has recalled multiple Active Pharmaceutical Ingredients manufactured in Italy upon receipt of a Rapid Alert Notification issued by The Italian Medicines Agency due to lack of good manufacturing practices.

Terminated cGMP deviation Gyma Laboratories Of Amer,Inc D-0021-2015
Class II · Moderate risk

fentaNYL 5000 mcg/250 mL

Lack of Assurance of Sterility: Firm received fentanyl from a supplier who recalled it because fliptop vial crimps were loose or missing.

Terminated Sterility / contamination Healix Infusion Therapy, Inc. NDC 75901-8015-04 D-1555-2014
Class II · Moderate risk

fentaNYL 2750 mcg/55 mL

Lack of Assurance of Sterility: Firm received fentanyl from a supplier who recalled it because fliptop vial crimps were loose or missing.

Terminated Sterility / contamination Healix Infusion Therapy, Inc. NDC 75901-8008-33 D-1554-2014
Class II · Moderate risk

fentaNYL 200 mcg/100 mL

Lack of Assurance of Sterility: Firm received fentanyl from a supplier who recalled it because fliptop vial crimps were loose or missing.

Terminated Sterility / contamination Healix Infusion Therapy, Inc. NDC 75901-8007-02 D-1553-2014
Class II · Moderate risk

fentaNYL 2500 mcg/250 mL

Lack of Assurance of Sterility: Firm received fentanyl from a supplier who recalled it because fliptop vial crimps were loose or missing.

Terminated Sterility / contamination Healix Infusion Therapy, Inc. NDC 75901-8002-04 D-1552-2014
Class II · Moderate risk

fentaNYL 1500 mcg/30 mL

Lack of Assurance of Sterility: Firm received fentanyl from a supplier who recalled it because fliptop vial crimps were loose or missing.

Terminated Sterility / contamination Healix Infusion Therapy, Inc. NDC 75901-8008-90 D-1551-2014

Recalls by year